Questions? Call 800-624-6242 About | Ordering | New Menu | Items in cart [0] SEARCH

PAPERBACK price:$33.75 add to cart Rights & Permissions Free PDF Access Sign in to download PDF book and chapters Free Resources Display this book on your site! Related Titles A National Cancer Clinical Trials System for the 21st Century:Reinvigorating the NCI Cooperative Group Program Multi-Center Phase III Clinical Trials and NCI Cooperative Groups: Workshop Summary Other Related Titles Improving the Quality of Cancer Clinical Trials: Workshop Summary (2008) National Cancer Policy Forum (NCPF) Citation Manager Export the bibliographic data for this book in your chosen format Web Search Builder Use this book's key terms to search within this book, across our collection, or across the Web. Skim This Chapter Skim this chapter and use this chapter's key terms to search within this book. Reference Finder Paste in your own text to find books that relate to your topic. Citation Manager . "Acronyms." Improving the Quality of Cancer Clinical Trials: Workshop Summary. Washington, DC: The National Academies Press, 2008. Please select a format: Page 107   E-mail Share on facebook Facebook Share on delicious Delicious Share on stumbleupon Stumble Share on twitter Twitter More Sharing ServicesMore The following HTML text is provided to enhance online readability. Many aspects of typography translate only awkwardly to HTML. Please use the page image as the authoritative form to ensure accuracy. Acronyms ACS American Cancer Society CLIA Clinical Laboratory Improvement Amendments CMS Centers for Medicare & Medicaid Services CT computed tomography CTEP Cancer Therapy Evaluation Program DCE dynamic contrast enhanced EGF epidermal growth factor ER estrogen receptor FDA Food and Drug Administration FDAMA Food and Drug Administration Modernization Act FDG [18F]-2-fluoro-2-deoxy-D-glucose FR Federal Register GCRC General Clinical Research Center HER-2 human epidermal growth factor receptor 2 IND investigational new drug Page 107 Front Matter (R1-R12) Introduction (1-2) New Clinical Trial Designs (3-39) Molecular Imaging (40-48) Screening for Predictive Markers (49-66) Costs of Clinical Trials (67-76) Regulatory Issues (77-88) Reports from the Case Study Discussion Groups (89-100) Concluding Remarks (101-101) References (102-106) Acronyms (107-108) Glossary (109-114) Appendix A: Workshop Agenda (115-122) Appendix B: Workshop Speakers, Moderators, and Invited Discussants (123-124)

Below are the first 10 and last 10 pages of uncorrected machine-read text (when available) of this chapter, followed by the top 30 algorithmically extracted key phrases from the chapter as a whole.
Intended to provide our own search engines and external engines with highly rich, chapter-representative searchable text on the opening pages of each chapter. Because it is UNCORRECTED material, please consider the following text as a useful but insufficient proxy for the authoritative book pages.

Do not use for reproduction, copying, pasting, or reading; exclusively for search engines.

OCR for page 107
Improving the Quality of Cancer Clinical Trials: Workshop Summary Acronyms ACS American Cancer Society CLIA Clinical Laboratory Improvement Amendments CMS Centers for Medicare & Medicaid Services CT computed tomography CTEP Cancer Therapy Evaluation Program DCE dynamic contrast enhanced EGF epidermal growth factor ER estrogen receptor FDA Food and Drug Administration FDAMA Food and Drug Administration Modernization Act FDG [18F]-2-fluoro-2-deoxy-D-glucose FR Federal Register GCRC General Clinical Research Center HER-2 human epidermal growth factor receptor 2 IND investigational new drug

OCR for page 108
Improving the Quality of Cancer Clinical Trials: Workshop Summary IRAT Image Response Assessment Team IRB Institutional Review Board LBNL Lawrence Berkeley National Laboratory MALDI matrix assisted laser desorption/ionization MedPAC Medicare Payment Advisory Commission MRI magnetic resonance imaging MSKCC Memorial Sloan-Kettering Cancer Center mTOR mammalian target of rapamycin NCCS National Coalition for Cancer Survivorship NCI National Cancer Institute NIH National Institutes of Health NSCLC non-small cell lung cancer PARP poly(ADP-ribose) polymerase PET positron emission tomography PhRMA Pharmaceutical Research and Manufacturers of America pre-IDE preinvestigation device exemption PSA prostate-specific antigen RECIST Response Evaluation Criteria in Solid Tumors SOP standard operating procedure SPA special protocol assessment SPECT single photon emission computed tomography SPORE Specialized Program of Research Excellence TBAC Tissue Banking Analysis Center TGen Translational Genomics Research Institute TNF tumor necrosis factor VEGF vascular endothelial growth factor